Ascendis Pharma
$227.87Change from previous close: +0.25%Absolute change: +$0.56
At a glance
- Revenue growth
- +98.03%
- 2025 vs 2024
- Net margin
- -31.7%
- 2024: -104.0%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | 720 | 364 | 267 | 51.2 |
| Cost of revenue | 94.9 | 44.3 | 44.4 | 12.1 |
| Gross profit | 625 | 319 | 222 | 39.0 |
| Selling, general and administrative | 448 | 284 | 264 | 216 |
| Research and development | 304 | 307 | 413 | 380 |
| Operating income | -136 | -279 | -456 | -562 |
| EBIT | -132 | -308 | -430 | -547 |
| EBITDA | -114 | -290 | -411 | -529 |
| Interest expense | 80.6 | 65.5 | 44.1 | 30.7 |
| Pre-tax income | -213 | -373 | -474 | -578 |
| Income tax | 15.4 | 4.8 | 7.3 | 5.4 |
| Net income | -228 | -378 | -481 | -583 |
| Net income to common shareholders | -228 | -378 | -481 | -583 |
| Basic EPS | -3.76 | -6.53 | -8.55 | -10.40 |
| Diluted EPS | -3.76 | -6.53 | -8.55 | -10.40 |
| Average shares (basic) | 60.6 | 57.9 | 57.9 | 56.1 |
| Average shares (diluted) | 60.6 | 57.9 | 57.9 | 56.1 |